研究方案:COPD嗜酸性粒细胞引导减少吸入性糖皮质激素(COPERNICOS):一项随机、双盲、多中心、四臂干预临床试验,探讨嗜酸性粒细胞引导的、时间更新的个体化吸入性糖皮质激素减量治疗及预防性低剂量阿奇霉素治疗在重度或极重度慢性阻塞性肺疾病患者中的应用
COPERNICOS是一项正在招募的随机、双盲、多中心、四臂析因干预临床试验,计划纳入444例专科确诊的COPD GOLD风险E级和/或FEV1<30%且正在使用ICS的患者,随访一年。患者按1:1:1:1随机分配至嗜酸性粒细胞引导ICS减量联合低剂量阿奇霉素、嗜酸性粒细胞引导ICS治疗联合安慰剂、继续ICS联合低剂量阿奇霉素或继续ICS联合安慰剂四组。主要终点为365天内需住院的COPD急性加重次数和/或死亡。
要点
- COPERNICOS试验计划纳入444例重度或极重度COPD患者,随访一年。
- 嗜酸性粒细胞引导组在血嗜酸性粒细胞<0.3×10^9细胞/L时暂停ICS治疗。
- 低剂量阿奇霉素为250 mg每周三次,双盲给药,主要终点为365天内需住院的COPD急性加重和/或死亡。
核心结论
- 该试验旨在探讨嗜酸性粒细胞引导的个体化ICS减量策略能否安全减少ICS过度治疗及副作用,以及口服低剂量预防性阿奇霉素250 mg每周三次能否减少COPD急性加重并改善存活且院外时间。
- 作者认为,嗜酸性粒细胞引导的ICS减量干预可能为安全减少ICS严重不良反应(如细菌感染)提供有用工具,且许多医生已在实践低剂量阿奇霉素预防,本试验将提供其是否有效的证据。
研究设计与样本
- 正在招募的随机、双盲、多中心、四臂析因干预临床试验,计划招募444例专科确诊的COPD GOLD风险E级和/或FEV1<30%且目前使用ICS的患者。
- 患者随访一年,按1:1:1:1随机分配至四组:(1)嗜酸性粒细胞引导ICS减量联合低剂量阿奇霉素;(2)嗜酸性粒细胞引导ICS治疗联合安慰剂;(3)继续ICS联合低剂量阿奇霉素;(4)继续ICS联合安慰剂。
- 嗜酸性粒细胞引导ICS减量组每3个月测量血嗜酸性粒细胞,若<0.3×10^9细胞/L则暂停ICS治疗。
- 阿奇霉素/安慰剂双盲给药,每周三次。
- 主要终点为365天内需住院的COPD急性加重次数和/或死亡。
关键数值与推荐
- 嗜酸性粒细胞引导ICS减量组:血嗜酸性粒细胞<0.3×10^9细胞/L时暂停ICS治疗。
- 低剂量阿奇霉素方案:口服250 mg每周三次。
- 主要终点:365天内需住院的COPD急性加重次数和/或死亡。
- 计划样本量:444例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhaled corticosteroid (ICS) is frequently used for COPD. Based on the considerable adverse effects and the knowledge that many such patients do not gain benefit from this treatment, it remains unresolved whether ICS treatment can be managed with lower doses, or via an ICS-sparing strategy with periods with and without this medicine. The blood eosinophil count is a useful biomarker for steroid-responsive airway inflammation, and we want to investigate whether an individualized and eosinophil-guided approach on ICS treatment reduces ICS over-treatment and side effects. High-dose (500 mg thrice weekly or 250 mg daily) long-term azithromycin has been shown to reduce acute exacerbations of COPD in selected patients. Frequent gastro-intestinal adverse effects remain a challenge, but many patients tolerate lower doses; however, the effect of the treatment at lower doses is unknown, although many physicians prefer such doses. We want to investigate whether oral low-dose prophylactic azithromycin 250 mg three times weekly reduces acute exacerbations of COPD and improves time alive and out of hospital. METHODS: This is an ongoing, actively recruiting randomized, double-blinded, multicenter, four-arm factorial intervention clinical trial aiming to recruit 444 patients with specialist verified COPD GOLD risk class E and/or FEV1 < 30% who are currently on ICS. The patients are followed for one year and are randomized 1:1:1:1 to one of the four treatment arms: (1) eosinophil-guided ICS-sparing treatment and low-dose azithromycin, (2) eosinophil-guided ICS treatment and placebo, (3) continued ICS treatment and low-dose azithromycin, or (4) continued ICS treatment and placebo. If blood-eosinophils (measured every 3 months) are < 0.3 × 109 cells/L, ICS treatment will be paused in the arms with eosinophil-guided ICS-sparing treatment. Azithromycin/placebo is double-blinded and administered three times weekly. The primary endpoint is the number of hospitalization-requiring COPD exacerbations and/or death within 365 days. DISCUSSION: Severe ICS-adverse effects like bacterial infections should be reduced. The ICS-sparing intervention, we test, may provide a useful tool to do this safely. Azithromycin low-dose prophylaxis is practiced by many physicians. This trial will provide evidence of whether this is effective. TRIAL REGISTRATION: ClinTrials.gov. NCT04481555. Registered on 14 AUG 2020, https://clinicaltrials.gov/study/NCT04481555 .
引用
- Rønn C, Bonnesen B, Alispahic IA, et al. Study protocol: COPD-eosinophil-guided reduction of inhaled corticosteroids (COPERNICOS) : A randomized, double-blinded, multicenter, four-arm intervention clinical trial on eosinophil-guided time-updated person-specific reduction of inhaled corticosteroid therapy and prophylactic low dose Azithromycin therapy in patients with severe or very severe chronic obstructive pulmonary disease (COPD). Trials. 2025. PMID: 40898355. doi:10.1186/s13063-025-09032-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。